Orthofix cuts 2026 outlook, sees net sales $838 million-$848 million

Orthofix Medical, Inc.

Orthofix Medical, Inc.

OFIX

0.00
  • Orthofix updated its full-year 2026 outlook following CMS billing changes tied to the FDA’s April 16, 2026 final order reclassifying non-invasive bone growth stimulators from Class III to Class II.
  • Average Medicare reimbursement for HCPCS codes E0747, E0748, E0760 is expected to fall about 10% for dates of service on or after May 18, 2026.
  • Net sales are now projected at $838 million to $848 million; non-GAAP adjusted EBITDA at $90 million to $93 million.
  • Positive free cash flow is no longer expected for 2026.
  • The company’s three-year financial targets were withdrawn; additional CMS reimbursement changes could prompt further revisions to guidance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orthofix Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-233429), on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.